Dose-escalated icotinib in frail, older adults patients with <i>EGFR</i>-mutant lung adenocarcinoma: real-world efficacy and safety in a high-risk cohort.

Front Oncol · 2025 · PMC12754169 · PMID 41479790

Europe PMC DOI

hedged sentence

0.0940

closest p · 1.9× alpha

0.0940

boldest claim

The sentences

a numerical trendp=0.094so close (0.05 < p ≤ 0.1)

Subgroup analyses Metastatic burden significantly stratified PFS (p=0.001), while a numerical trend was observed for OS (p=0.094), indicating poorer outcomes in the subgroup with ≥2 metastatic organs ( Figure 5 ).

also in 1,012 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.

Dose-escalated icotinib in frail, older adults patients with &lt;i&gt;EGFR&lt;/i&gt;-mutant lung adenocarcinoma: real-world efficacy and safety in a high-risk cohort.

The sentences

Dose-escalated icotinib in frail, older adults patients with <i>EGFR</i>-mutant lung adenocarcinoma: real-world efficacy and safety in a high-risk cohort.